---
title: "Chandan Healthcare Analysis: Emerging Powerplay in the Indian Diagnostics Sector (FY26)"
description: "Detailed analysis of Chandan Healthcareâ€™s Q3 FY26 performance, expansion strategy, EBITDA potential, capex plans, and growth triggers in the Indian diagnostics industry."
slug: "chandan-healthcare-analysis-indian-diagnostics-fy26"
keywords: ["Chandan Healthcare", "Indian diagnostics sector", "diagnostic companies India", "healthcare stocks India", "diagnostic sector growth", "small cap healthcare India"]
author: "Priyanshu Jain"
date: "2026-02-22"
image: /assets/22022026chandanhealthcare.png

---

# Chandan Healthcare = Vaibhav Suryaavanshi of Indian Diagnostics? ğŸ

![alt text](assets/image.png)

Some companies defend.  
Some attack.  

Chandan Healthcare is clearly playing in the powerplay.

> Author: [Priyanshu Jain](https://in.linkedin.com/in/priyanshujain2032) ,Date: 2026-02-22

---

## ğŸ“Š Q3 FY26 Snapshot

| Metric | Value | Growth |
|--------|--------|--------|
| Revenue | â‚¹65.77 Cr | +20% YoY |
| EBITDA | â‚¹12.61 Cr | +39% YoY |
| EBITDA Margin | 19.17% | â€” |
| PAT | â‚¹4.54 Cr | â€” |

> Note: â‚¹2.2 Cr one-time gratuity impact due to new labour code.

---

## ğŸ¥ Business Model: Not Asset-Light. Not Minimal.

Unlike traditional asset-light diagnostic chains, Chandan builds **8,000â€“9,000 sq ft comprehensive centres** offering:

- Pathology  
- Radiology (MRI, CT)  
- Corporate health check-ups  
- Government PPP projects  
- Direct B2C services  
- Franchise network  

Everything under one roof.

---

## ğŸ’° Segment EBITDA Potential

| Segment | EBITDA Potential |
|----------|------------------|
| B2C (Mature Centres) | 40â€“45% |
| B2G | 30â€“40% |
| B2B / Franchise | ~35% |

As centres mature â†’ **Operating leverage improves significantly.**

Same infra. Higher utilisation. Better margins.

---

## ğŸš€ Expansion Mode: ON

- 6 comprehensive centres added  
- 18 labs launched  
- Presence in 13 states  
- 9 new labs launching  
- Genome Lab (Lucknow)  
- PET Scan facility (Gorakhpur)

### Capex Plan
â‚¹100 Cr over 3 years  
~â‚¹1 Cr per lab

---

## ğŸ¤ Jeena Sikho Partnership

- â‚¹2.5â€“3 lakh/day revenue currently  
- ~30% utilisation  
- Target: 100% utilisation within 1 year  

If utilisation scales â†’ margin expansion follows.

---

## ğŸ”¥ Big Trigger: Punjab + Guwahati Project

- â‚¹55 Cr annual revenue visibility  
- 10-year contract  
- Cash collected directly from patients  

If executed well â€” FY27 could look very different.

---

## ğŸ¯ Strategic Positioning

Theyâ€™re not copying Dr Lal PathLabs.  
Theyâ€™re building their own integrated format.

Young. Aggressive. Scaling fast.

Like Vaibhav Suryaavanshi â€”  
Not waiting for the pitch to settle.

---

## ğŸ§  Final Thoughts

Execution will decide whether ambition converts into sustained profitability.

But one thing is clear:

Chandan Healthcare is not playing defensively.

Itâ€™s playing to dominate early overs.

```mermaid
flowchart TD
    A[Chandan Healthcare<br>Integrated Diagnostic Model] 
    
    A --> B[High Capex Comprehensive Centres<br>8000 to 9000 sq ft]
    
    B --> C1[B2C Services<br>40â€“45% EBITDA Potential]
    B --> C2[B2G PPP Contracts<br>30â€“40% EBITDA Potential]
    B --> C3[B2B Franchise<br>~35% EBITDA Potential]
    
    C1 --> D[Volume Growth]
    C2 --> D
    C3 --> D
    
    D --> E[Higher Utilisation]
    E --> F[Operating Leverage]
    F --> G[Margin Expansion]
    
    G --> H[Stronger Cash Flows]
    H --> I[Expansion: New Labs + Genome + PET + Punjab/Guwahati]
    
    I --> A
```

---

### Whatâ€™s your view on emerging diagnostic players beyond the obvious giants?